The Korean journal of internal medicine

  • 제31권2호
  • /
  • Pages.242-252
  • /
  • 2016
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma

  • Song, Myeong Jun (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Bae, Si Hyun (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, June Sung (Department of Internal Medicine, Inje University Ilsan Paik Hospital) ;
  • Lee, Sung Won (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Song, Do Seon (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • You, Chan Ran (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Choi, Jong Young (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Seung Kew (Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
  • 투고 : 2014.04.26
  • 심사 : 2015.11.18
  • 발행 : 2016.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: We compared the recurrence of hepatocellular carcinoma (HCC) and the survival of patients who received radiofrequency ablation (RFA) after transarterial chemoembolization (TACE) with patients treated with TACE or RFA alone. Methods: This study included 201 patients with HCC, who were consecutively enrolled at Seoul St. Mary's Hospital between December 2004 and February 2010. Inclusion criteria were a single $HCC{\leq}5.0cm$ or up to three $HCCs{\leq}3.0cm$. We used a propensity score model to compare HCC patients (n = 87) who received RFA after TACE (TACE + RFA) with those who received TACE (n = 71) or RFA alone (n = 43). Results: The median follow-up period was 33.3 months (range, 6.8 to 80.9). The TACE + RFA group showed significantly lower local recurrence than the RFA or TACE groups (hazard ratio [HR], 0.309; 95% confidence interval [CI], 0.130 to 0.736; p = 0.008; and HR, 0.352; 95% CI, 0.158 to 0.787; p = 0.011, respectively). The overall survival was significantly better in the TACE + RFA group compared to the RFA group (HR, 0.422; 95% CI, 0.185 to 0.964; p = 0.041). However, the survival benefit was not different between the TACE + RFA and TACE groups (p = 0.124). Subgroup analysis showed that among patients with a tumor size < 3 cm, the TACE + RFA group had significantly better long-term survival than those in the TACE or RFA groups (p = 0.017, p = 0.004, respectively). Conclusions: TACE + RFA combination treatment showed favorable local recurrence and better overall survival rates in early-stage HCC patients. Patients with tumors < 3 cm are likely to benefit more from TACE + RFA combination treatment. Additional studies are needed for the selection of suitable HCC patients for TACE + RFA treatment.

키워드

과제정보

연구 과제 주관 기관 : Ministry of Health, Welfare and Family Affairs

참고문헌

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156. https://doi.org/10.1002/ijc.1440
  2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750. https://doi.org/10.1056/NEJM199903113401001
  3. Bruix J, Sherman M, Llovet JM, et al. Conclusions of the Barcelona-2000 EASL conference: European Association for the Study of the Liver. J Hepatol 2001;35:421-430. https://doi.org/10.1016/S0168-8278(01)00130-1
  4. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-240. https://doi.org/10.1148/radiol.2281020718
  5. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127:1714-1723. https://doi.org/10.1053/j.gastro.2004.09.003
  6. Kagawa T, Koizumi J, Kojima S, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 2010;116:3638-3644. https://doi.org/10.1002/cncr.25142
  7. Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol 2007;17:684-692. https://doi.org/10.1007/s00330-006-0461-5
  8. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47:82-89.
  9. N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009;50:1475-1483. https://doi.org/10.1002/hep.23181
  10. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022. https://doi.org/10.1002/hep.24199
  11. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442. https://doi.org/10.1053/jhep.2003.50047
  12. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-661. https://doi.org/10.1148/radiology.210.3.r99fe40655
  13. McGhana JP, Dodd GD 3rd. Radiofrequency ablation of the liver: current status. AJR Am J Roentgenol 2001;176:3-16. https://doi.org/10.2214/ajr.176.1.1760003
  14. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000;214:761-768. https://doi.org/10.1148/radiology.214.3.r00mr02761
  15. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities: part II. J Vasc Interv Radiol 2001;12:1135-1148. https://doi.org/10.1016/S1051-0443(07)61670-4
  16. Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol 2003;10:338-347. https://doi.org/10.1245/ASO.2003.07.017
  17. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711. https://doi.org/10.1093/jnci/djn134
  18. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S179-S188. https://doi.org/10.1053/j.gastro.2004.09.032
  19. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-773. https://doi.org/10.1002/hep.23725
  20. Golfieri R, Cappelli A, Cucchetti A, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 2011;53:1580-1589. https://doi.org/10.1002/hep.24246
  21. Akamatsu M, Yoshida H, Obi S, et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 2004;24:625-629. https://doi.org/10.1111/j.1478-3231.2004.0963.x
  22. Marelli L, Stigliano R, Triantos C, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006;32:594-606. https://doi.org/10.1016/j.ctrv.2006.08.002
  23. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60. https://doi.org/10.1055/s-0030-1247132
  24. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281. https://doi.org/10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
  25. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560. https://doi.org/10.1097/00001648-200009000-00011
  26. Sohn MH, Jeong YJ, Jeong HJ, et al. F-18 FDG PET/CT findings of huge cholesterol granuloma in multiple ribs. Clin Nucl Med 2011;36:942-944. https://doi.org/10.1097/RLU.0b013e31821a2778
  27. Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008;8:2547-2557. https://doi.org/10.1111/j.1600-6143.2008.02409.x
  28. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-328. https://doi.org/10.1097/01.sla.0000201480.65519.b8
  29. Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005;11:1117-1126. https://doi.org/10.1002/lt.20469
  30. Hsu CY, Huang YH, Chiou YY, et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl 2011;17:556-566. https://doi.org/10.1002/lt.22273
  31. Camma C, Di Marco V, Orlando A, et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 2005;42:535-540. https://doi.org/10.1016/j.jhep.2004.11.042
  32. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 2005;103:1201-1209. https://doi.org/10.1002/cncr.20892
  33. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg 2008;12:183-191. ------------------- https://doi.org/10.1007/s11605-007-0276-y

피인용 문헌

  1. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update vol.11, pp.4, 2017, https://doi.org/10.1007/s12072-017-9799-9
  2. Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma vol.8, pp.2, 2016, https://doi.org/10.18632/oncotarget.13813
  3. Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Bar vol.19, pp.6, 2016, https://doi.org/10.3348/kjr.2018.19.6.1130
  4. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Tre vol.73, pp.3, 2019, https://doi.org/10.4166/kjg.2019.73.3.167
  5. Early experience of combination therapy of transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma measuring 3–7 cm vol.29, pp.1, 2016, https://doi.org/10.4103/ijri.ijri_352_18
  6. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of vol.19, pp.1, 2016, https://doi.org/10.1186/s12885-019-6237-5
  7. Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma vol.12, pp.1, 2016, https://doi.org/10.4251/wjgo.v12.i1.92
  8. Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and Its Role in Multidisciplinary Therapy vol.12, pp.10, 2020, https://doi.org/10.3390/cancers12102955
  9. The clinical effects of ultrasound-guided microwave ablation in the treatment of primary hepatic carcinoma : Protocol for a retrospective clinical observation vol.100, pp.48, 2016, https://doi.org/10.1097/md.0000000000028045
  10. Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis vol.10, pp.23, 2021, https://doi.org/10.1002/cam4.4350
  11. Image-guided microwave ablation of hepatocellular carcinoma (≤5.0 cm): is MR guidance more effective than CT guidance? vol.21, pp.1, 2021, https://doi.org/10.1186/s12885-021-08099-7
  12. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis vol.19, pp.1, 2016, https://doi.org/10.1186/s12957-021-02188-4
  13. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? vol.13, pp.12, 2016, https://doi.org/10.4251/wjgo.v13.i12.1896
  14. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression vol.39, pp.1, 2016, https://doi.org/10.1080/02656736.2021.1998660